A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
Status:
Enrolling by invitation
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus
(EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China
and Southeast Asia. The NPC cells are poorly differentiated or undifferentiated with a high
incidence of lymphatic and hematological dissemination. Because of the inherent anatomic
constraints and a high degree of radiosensitivity, radiotherapy (RT) has been the primary
treatment for NPC patients.
NPC is also a chemosensitive tumor. Various modes of combined chemoradiotherapy have been
used to treat NPC patients with advanced-stage diseases during recent 20 years. However,
treatment outcome for locoregionally advanced NPC is still unsatisfactory.
Phase:
Phase 3
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
China Medical University Hospital Kaohsiung Veterans General Hospital. Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taichung Veterans General Hospital